Precision Intensification in Metastatic Prostate Cancer
Mené sur 599 patients atteints d'un cancer métastatique de la prostate présentant des altérations au niveau des gènes de réparation de l'ADN par recombinaison homologue, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression à 3 ans, et la toxicité de l'ajout du talazoparib à l'enzalutamide
The treatment of advanced prostate cancer has undergone significant improvements, with two developments proven to be especially transformative. The first advance was the establishment of treatment intensification in patients with metastatic castration-sensitive prostate cancer (hereafter referred to as metastatic androgen pathway modulation–sensitive [APMS] disease, in accordance with the recently updated Prostate Cancer Working Group 4 framework).1 The second advance was the identification of alterations in homologous recombination repair genes as predictive biomarkers for poly(ADP-ribose) polymerase (PARP) inhibitor sensitivity in patients with advanced disease. Alterations in homologous recombination repair genes have heterogeneous effects in patients with advanced prostate cancer, and BRCA1 . . .
New England Journal of Medicine , éditorial, 2026